These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 27075128)

  • 21. Interleukin-1 receptor antagonist, soluble tumor necrosis factor-alpha receptor type I and II, and soluble E-selectin serum levels in multiple sclerosis patients receiving weekly intramuscular injections of interferon-beta1a.
    Perini P; Tiberio M; Sivieri S; Facchinetti A; Biasi G; Gallo P
    Eur Cytokine Netw; 2000 Mar; 11(1):81-6. PubMed ID: 10705303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IFN-beta1a and IFN-beta1b have different patterns of influence on cytokines.
    Sega S; Wraber B; Mesec A; Horvat A; Ihan A
    Clin Neurol Neurosurg; 2004 Jun; 106(3):255-8. PubMed ID: 15177779
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systemic sclerosis fibroblasts show specific alterations of interferon-γ and tumor necrosis factor-α-induced modulation of interleukin 6 and chemokine ligand 2.
    Antonelli A; Fallahi P; Ferrari SM; Giuggioli D; Colaci M; Di Domenicantonio A; Ferri C
    J Rheumatol; 2012 May; 39(5):979-85. PubMed ID: 22422499
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis.
    Brod SA; Marshall GD; Henninger EM; Sriram S; Khan M; Wolinsky JS
    Neurology; 1996 Jun; 46(6):1633-8. PubMed ID: 8649562
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis.
    Hamamcioglu K; Reder AT
    Mult Scler; 2007 May; 13(4):459-70. PubMed ID: 17463069
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IFN-beta1a inhibits the secretion of Th17-polarizing cytokines in human dendritic cells via TLR7 up-regulation.
    Zhang X; Jin J; Tang Y; Speer D; Sujkowska D; Markovic-Plese S
    J Immunol; 2009 Mar; 182(6):3928-36. PubMed ID: 19265172
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo effect of interferon-beta 1a on interleukin-12 and TGF-beta(1) cytokines in patients with relapsing-remitting multiple sclerosis.
    Losy J; Michałowska-Wender G
    Acta Neurol Scand; 2002 Jul; 106(1):44-6. PubMed ID: 12067328
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of combination therapy of beta-interferon 1a and prednisone on serum immunologic markers in patients with multiple sclerosis.
    Salama HH; Kolar OJ; Zang YC; Zhang J
    Mult Scler; 2003 Feb; 9(1):28-31. PubMed ID: 12617264
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity of an interferon-beta1a product.
    Kauffman MA; Sterin-Prync A; Papouchado M; González E; Vidal AJ; Grossberg SE; Chuppa S; Odoriz B; Vrech C; Diez RA; Ferro HH
    Int J Immunopathol Pharmacol; 2011; 24(2):499-504. PubMed ID: 21658324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology.
    Hu X; Miller L; Richman S; Hitchman S; Glick G; Liu S; Zhu Y; Crossman M; Nestorov I; Gronke RS; Baker DP; Rogge M; Subramanyam M; Davar G
    J Clin Pharmacol; 2012 Jun; 52(6):798-808. PubMed ID: 21680782
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
    Ochi H; Feng-Jun M; Osoegawa M; Minohara M; Murai H; Taniwaki T; Kira J
    J Neurol Sci; 2004 Jul; 222(1-2):65-73. PubMed ID: 15240198
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Deep morphea induced by interferon-β1b injection.
    Lee EY; Glassman SJ
    JAAD Case Rep; 2016 May; 2(3):236-8. PubMed ID: 27408930
    [No Abstract]   [Full Text] [Related]  

  • 33. Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis.
    De Stefano N; Curtin F; Stubinski B; Blevins G; Drulovic J; Issard D; Shotekov P; Gasperini C;
    Mult Scler; 2010 Jul; 16(7):888-92. PubMed ID: 20200197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination therapy with interferon beta-1a and sesame oil in multiple sclerosis.
    Faraji F; Hashemi M; Ghiasabadi A; Davoudian S; Talaie A; Ganji A; Mosayebi G
    Complement Ther Med; 2019 Aug; 45():275-279. PubMed ID: 31331574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interferon-beta1a for the treatment of multiple sclerosis.
    Clerico M; Contessa G; Durelli L
    Expert Opin Biol Ther; 2007 Apr; 7(4):535-42. PubMed ID: 17373904
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interferon-β 1a Modulates Expression of RAGE but Not S100A12 and Nuclear Factor-κB in Multiple Sclerosis Patients.
    Asadikaram G; Noroozi S; Ebrahimi Meimand HA; Sanjari M; Zainodini N; Khoramdelazad H; Shahrokhi N; Kazemi Arababadi M
    Neuroimmunomodulation; 2016; 23(5-6):345-351. PubMed ID: 28433998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interferon-beta treatment in multiple sclerosis patients decreases the number of circulating T cells producing interferon-gamma and interleukin-4.
    Furlan R; Bergami A; Lang R; Brambilla E; Franciotta D; Martinelli V; Comi G; Panina P; Martino G
    J Neuroimmunol; 2000 Nov; 111(1-2):86-92. PubMed ID: 11063825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis.
    Rudick RA; Ransohoff RM; Lee JC; Peppler R; Yu M; Mathisen PM; Tuohy VK
    Neurology; 1998 May; 50(5):1294-300. PubMed ID: 9595977
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interferon-beta-1a: A Review of its Pharmacological Properties and Therapeutic Potential in Multiple Sclerosis.
    Holliday SM; Benfield P
    BioDrugs; 1997 Oct; 8(4):317-30. PubMed ID: 18020522
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of interferon-beta on interleukin-10 in multiple sclerosis patients.
    Ersoy E; Kuş CN; Sener U; Coker I; Zorlu Y
    Eur J Neurol; 2005 Mar; 12(3):208-11. PubMed ID: 15693810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.